NCT01195311View on ClinicalTrials.gov

A Dose-escalation Study in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions

Solid Tumors and Hematologic Malignancy

Interventions

DRUG

INCB024360

INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.

Trial Locations (2)

Unknown

Chicago

Philadelphia

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY